Abstract
Drews discusses the case histories of several modern innovative drugs — bevacizumab, COX2 inhibitors, enfuvirtide, imatinib and natalizumab — and considers whether they can provide lessons for improving research and development strategies. The case histories of five modern drugs are taken as a basis for reflection on the state of drug discovery. Two issues intimately associated with drug research are highlighted: the nature of the intellectual process leading to new discoveries; and the possibility that the principle of selective efficacy, which has guided drug research from its beginnings, might need modification, at least in some areas of pharmacotherapy.

This publication has 41 references indexed in Scilit: